- Home
- NGD vs LIVN Comparison
NGD vs LIVN Comparison
Compare NGD & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- LIVN
- Stock Information
- Founded
- NGD N/A
- LIVN 1987
- Country
- NGD Canada
- LIVN United Kingdom
- Employees
- NGD N/A
- LIVN N/A
- Industry
- NGD
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NGD
- LIVN Health Care
- Exchange
- NGD Nasdaq
- LIVN Nasdaq
- Market Cap
- NGD 2.4B
- LIVN 2.6B
- IPO Year
- NGD 2004
- LIVN 1993
- Fundamental
- Price
- NGD $2.83
- LIVN $47.44
- Analyst Decision
- NGD Buy
- LIVN Buy
- Analyst Count
- NGD 4
- LIVN 7
- Target Price
- NGD $3.23
- LIVN $67.14
- AVG Volume (30 Days)
- NGD 14.5M
- LIVN 447.2K
- Earning Date
- NGD 02-19-2025
- LIVN 02-25-2025
- Dividend Yield
- NGD N/A
- LIVN N/A
- EPS Growth
- NGD N/A
- LIVN 759.09
- EPS
- NGD 0.02
- LIVN 0.43
- Revenue
- NGD $861,500,000.00
- LIVN $1,241,739,000.00
- Revenue This Year
- NGD $19.21
- LIVN $10.18
- Revenue Next Year
- NGD $28.63
- LIVN $5.43
- P/E Ratio
- NGD $119.51
- LIVN $110.76
- Revenue Growth
- NGD 14.85
- LIVN 11.04
- 52 Week Low
- NGD $1.10
- LIVN $43.15
- 52 Week High
- NGD $3.25
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- NGD 46.34
- LIVN 44.11
- Support Level
- NGD $2.75
- LIVN $46.75
- Resistance Level
- NGD $3.07
- LIVN $49.96
- Average True Range (ATR)
- NGD 0.15
- LIVN 1.24
- MACD
- NGD -0.03
- LIVN -0.09
- Stochastic Oscillator
- NGD 18.75
- LIVN 21.50
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.